ERAS and breast cancer: While most evidence suggests they are also clinically resistant to tamoxifen and fulvestrant/ICI4, 8, 9, recent studies demonstrated increased prevalence of ERα mutations in breast cancers of patients treated with aromatase inhibitors, but not in patients treated with fulvestrant5, or tamoxifen6.